In initial experiments we examined the classical CD56bright and CD56dim NK cell subpopulations in healthy donors, untreated AML patients at time of diagnosis, AML patients in remission following chemotherapy and AML patients following treatment with HDC plus low dose IL-2. This evidence concerns the gene IL2 and acute myeloid leukemia.